{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P00813",
      "entity_text" : "ADA",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ04344",
      "entity_text" : "IFX",
      "features" : [ {
        "modification_type" : "unknown",
        "feature_type" : "modification"
      } ],
      "entity_type" : "gene_or_gene_product"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "When we compared ADA positive sera which showed seroconversion for the first time with ADA negative sera which were taken at the time points (6.1 +/- 1.3 months) when ADA negative patients presented impaired clinical response, serum trough levels of IFX were significantly decreased in the ADA positive sera compared with the ADA negative sera (0.09 +/- 0.03 vs. 2.48 +/- 0.33 mug/mL; p < 0.0001).",
  "reading_complete" : "2020-08-08T15:34:33Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-08T15:30:58Z",
  "trigger" : "decreased",
  "evidence" : [ "ADA-positive sera which showed seroconversion for the first time with ADA-negative sera which were taken at the time points (6.1 +/- 1.3 months) when ADA-negative patients presented impaired clinical response, serum trough levels of IFX were significantly decreased" ],
  "pmc_id" : "5028026",
  "score" : 0
}